Novartis Scemblix® demonstrates sustained response rate in 48-week follow-up in patients with chronic myeloid leukemia

/PRNewswire/ -- Novartis today announced new 48-week data from the Phase III ASCEMBL trial of Scemblix® (asciminib) demonstrating that the results observed in...

Related Keywords

United States ,East Hanover ,Pennsylvania ,Philadelphia ,America ,American ,Michaelj Mauro ,Jeff Legos ,Julie Masow ,Sloan Simpson ,Prnewswire Novartis ,Floriana Riccio Furnari ,Novartis Oncology Congress Hub ,Twitter ,Novartis Oncology Communications ,Novartis Us External Communications ,Novartis ,Exchange Commission ,Pfizer ,Approval Program ,Nj Novartis Pharmaceuticals Corporation ,American Society Of Hematology Annual Meeting Exposition ,Novartis Pharmaceuticals Corp ,American Society ,Hematology Annual Meeting ,Myeloproliferative Neoplasms Program Leader ,Memorial Sloan Kettering Cancer Center ,Executive Vice President ,Global Head ,Hematology Development ,Novartis Commitment ,Prescribing Information ,Pharmaceuticals Corporation ,Safety Results ,Chronic Myeloid Leukemia ,Chronic Phase ,Tyrosine Kinase Inhibitors ,Randomized Study ,Provides Durable Molecular Response ,Primary Efficacy ,Allosteric Inhibitor ,Tyrosine Kinase Activity ,Reveals Significant ,Durable Responses ,Exhibits Safety ,Phasei Study ,Asciminib Plus Nilotinib ,Therapy Using Asciminib Plus Imatinib ,Myeloid Leukemia ,Previously Treated With ,Adult Patients With Newly Diagnosed ,More Tyrosine Kinase ,Patients With ,Pediatric Patients With Chronic Myeloid Leukemia ,Treatment Optimization ,Open Label ,Once Daily ,Newly Diagnosed Adult Patients ,Pediatric Patients ,Philadelphia Chromosome ,Positive Chronic Myeloid Leukemia ,Chronic Phase Treated ,Tyrosine Kinase ,Riccio Furnari ,Oncology Communications ,Novartis Us ,